Brief: Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis
19/12/2023 13:25
Dec 19 (Reuters) - Tiziana Life Sciences Ltd TLSA.O :
* TIZIANA LIFE SCIENCES DOSES FIRST PATIENT IN PHASE 2A
TRIAL OF
INTRANASAL FORALUMAB IN MULTIPLE SCLEROSIS
* TIZIANA LIFE SCIENCES LTD - POISED TO ACCELERATE
ENROLLMENT AND
ANTICIPATE DATA READOUT IN Q4 2024
Source text for Eikon: ID:nGNX6GBFNp
Further company coverage: TLSA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tiziana Life Sciences
See all newsTiziana's experimental MS treatment meets main goals in mid-stage study
Brief: Tiziana Life Sciences - Submits Request To FDA For Orphan Drug Designation For Intranasal Foralumab For Msa
Brief: Tiziana Announces Last Patient Completes Last Visit In Phase 2A Inform-MS Trial Of Intranasal Foralumab
Brief: Tiziana Announces Last Patient Successfully Dosed In Its Phase 2 Inform-MS Trial
Brief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis